Domantis

Domantis Ltd. develops antibody molecules, providing bispecific human domain antibodies targeting cytokine targets for inflammatory diseases, tumor antigens present on the same tumor cells, and tumor growth/angiogenic factors for solid tumors; human domain antibodies with customized serum half-life, tailored to achieve the desired therapeutic effect; human domain antibodies for multiple therapeutic targets suitable for inhibiting receptor targets; and injectable and non-injectable human domain antibodies for treating pulmonary and gastrointestinal diseases.